Synonym
NSC756093; NSC-756093; NSC 756093;
IUPAC/Chemical Name
4-(2-Hydroxyethyl)-6-methoxy-9-phenyl-4,9-dihydrofuro[3,4-b]quinolin-1(3H)-one
InChi Key
SMEJQLRLHKWIFV-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H19NO4/c1-24-14-7-8-15-16(11-14)21(9-10-22)17-12-25-20(23)19(17)18(15)13-5-3-2-4-6-13/h2-8,11,18,22H,9-10,12H2,1H3
SMILES Code
O=C1OCC(N2CCO)=C1C(C3=CC=CC=C3)C4=C2C=C(OC)C=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
NSC756093 is a potent inhibitor of the GBP1:PIM1 interaction.
In vitro activity:
The inhibition of the GBP1:PIM1 interaction by NSC756093 was dose-dependent (Figure 2B) and statistically significant as compared with the control without drug (p < 0.001, Anova). To confirm the activity of the drug in cell lines, this study assessed the ability of NSC756093 to inhibit the GBP1:PIM1 interaction in SKOV3 cells.
Reference: J Med Chem. 2014 Oct 9;57(19):7916-32. https://pubmed.ncbi.nlm.nih.gov/25211704/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
337.38
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Andreoli M, Persico M, Kumar A, Orteca N, Kumar V, Pepe A, Mahalingam S, Alegria AE, Petrella L, Sevciunaite L, Camperchioli A, Mariani M, Di Dato A, Novellino E, Scambia G, Malhotra SV, Ferlini C, Fattorusso C. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem. 2014 Oct 9;57(19):7916-32. doi: 10.1021/jm5009902. Epub 2014 Sep 26. PMID: 25211704; PMCID: PMC4191604.
In vitro protocol:
Andreoli M, Persico M, Kumar A, Orteca N, Kumar V, Pepe A, Mahalingam S, Alegria AE, Petrella L, Sevciunaite L, Camperchioli A, Mariani M, Di Dato A, Novellino E, Scambia G, Malhotra SV, Ferlini C, Fattorusso C. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem. 2014 Oct 9;57(19):7916-32. doi: 10.1021/jm5009902. Epub 2014 Sep 26. PMID: 25211704; PMCID: PMC4191604.
1: Andreoli M, Persico M, Kumar A, Orteca N, Kumar V, Pepe A, Mahalingam S, Alegria AE, Petrella L, Sevciunaite L, Camperchioli A, Mariani M, Di Dato A, Novellino E, Scambia G, Malhotra SV, Ferlini C, Fattorusso C. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem. 2014 Oct 9;57(19):7916-32. doi: 10.1021/jm5009902. Epub 2014 Sep 26. PubMed PMID: 25211704; PubMed Central PMCID: PMC4191604.
